Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
For the full year FY25, net profit soared 12x to Rs 345 crore
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Subscribe To Our Newsletter & Stay Updated